Mediation on outstanding claims filed against Biogen Idec Inc. and its subsidiary Biogen Inc. (n/k/a Biogen Idec MA Inc.) over certain drugs for which Medicaid provides reimbursement (covered drugs) is still ongoing.
Along with several other major pharmaceutical and biotechnology…
The U.S. Department of Justice’s investigation of Genentech, Inc. relating to the promotion of RITUXAN, a cancer medication used in combination with other cancer medicines to treat non-Hodgkin’s lymphoma, is ongoing.
Biogen Idec Inc. markets RITUXAN in the U.S. in…
Biogen Idec Inc. continues to cooperate with the European Commission’s industry-wide antitrust inquiry into competitive conditions within the pharmaceutical sector.
As part of the inquiry that began on January 2008, the EC issued detailed questionnaires to about 100 companies, including the…
Biogen Idec Inc.’s wholly owned subsidiary, Biogen Idec MA, Inc., continues to contest the Massachusetts Department of Revenue’s US$38.9 million tax assessment.
On Sept. 12, 2006, the DOR issued a notice of assessment against Biogen Idec MA for US$38.9 million of…
A hearing in the arbitration filed by Biogen Idec Inc. against Genentech, Inc. alleging breach of their Collaboration Agreement is scheduled to conclude in December 2008.
On June 17, 2006, the Company filed a Demand for Arbitration against Genentech with…
Valeant Pharmaceuticals International is in the process of defending Barbara M. Shows’ product liability lawsuit on Permax pending in the Circuit Court of Jefferson Davis County, Miss.
On April 23, 2008, the Company was served a complaint in a case…